Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-90189892 in Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms
NCT06651229Phase 1Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2025
- Primary completion
- Aug 2027
- Countries
- 3
01
Overview
Phase 1, open-label trial of JNJ-90189892 in acute myeloid leukemia (AML) and myelodysplastic neoplasms (MDS) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Adverse Events by Severity and Dose-Limiting Toxicity. Started Mar 2025; status: active, not recruiting.
02
Drugs
JNJ-90189892
03
Conditions
acute myeloid leukemia (AML)myelodysplastic neoplasms (MDS)
Beyond the preview
Go deeper on NCT06651229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06651229.